# Nervonik

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nervonik

- Industry: Medical Devices & Equipment
- Headquarters: Los Angeles, US
- Website: www.nervonik.com/
- Total disclosed funding: $66M
- Latest round: Series B (Apr 27, 2026)
- Investors on record: 8

## About

Nervonik, Inc. develops advanced neuromodulation implants aimed at providing innovative therapeutic solutions for chronic neuropathic pain through electrical stimulation, enhancing patient quality of life. Nervonik, Inc. focuses on developing neuromodulation devices that address chronic neuropathic pain. The company founded by Aydin Babakhani (CEO) and is based in Los Angeles, US. In April 2026, Nervonik, Inc. raised USD 52.5 million in series B funding Co-led by new investors Sofinnova Partners and Amzak Capital Management, with participation from other new investors Elevage Medical Technologies, LP, Lumira Ventures and returning investors ShangBay Capital, Foothill Ventures, and US Venture Partners. Other unspecified investors also participated in this round. Nervonik specializes in the development of innovative neuromodulation implants designed to provide therapeutic solutions for chronic neuropathic pain. Their core product offerings include miniaturized, power-efficient neuromodulation devices that target the peripheral nervous system (PNS) to modulate nerve activity through electrical stimulation. These implants are intended to disrupt pain signals before they reach the brain, providing a narcotic-free alternative for pain management. Currently available for research purposes, Nervonik's implants are particularly beneficial for patients suffering from intractable discomfort due to conditions such as neuropathy. The company primarily serves medical professionals and researchers in North America and Europe, with a focus on improving patient quality of life through advanced technology in pain management. The revenue model for Nervonik is based on direct sales of their neuromodulation devices to medical institutions and research facilities, as well as potential partnerships with healthcare providers for broader distribution. Transactions typically involve the procurement of their flagship neuromodulation implants, which are supplied alongside a wearable wireless power transfer device that enhances functionality and comfort. These products are expected to be offered under a structured pricing plan that may include bulk purchasing options for hospitals and clinics. Additionally, the company may engage in subscription models for ongoing access to software updates and enhancements via the associated digital application, facilitating data sharing between patients and healthcare professionals. The company plans to use the April 2026 funding to support further development of its peripheral nerve stimulation system, advance its sensing capabilities, run clinical programs, and prepare for commercialization.

## Funding rounds

- Series B, Apr 27, 2026, $53M — Sofinnova Partners, US Venture Partners, Foothill Ventures, ShangBay Capital, Amzak Capital Management, Lumira Ventures, Elevage Medical Technologies, LP
- Series A, Mar 4, 2025, $13M — US Venture Partners, Correlation Ventures, Foothill Ventures

## Investors

- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series A, Series B
- Correlation Ventures (https://capitalatlas.ai/funds/correlation-ventures) — Series A
- Foothill Ventures (https://capitalatlas.ai/funds/foothill-ventures) — Series A, Series B
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series B
- ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series B
- Amzak Capital Management (https://capitalatlas.ai/funds/amzak-capital-management) — Series B
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series B
- Elevage Medical Technologies, LP — Series B